Sensex, Nifty Rangebound Ahead Of F&O Expiry; Coal India, DRL Gain

Shares of Cadila Healthcare added 1.3 percent intraday as it has received USFDA approval for Candesartan Cilexetil and hydrochlorothiazide tablets.

Zydus Cadila has received the final approval from the USFDA to market Candesartan Cilexetil and hydrochlorothiazide tablets USP in the strengths of 16mg/12.5 mg, 32mg/12.5mg and 32 mg/ 25 mg.

The drug combines an angiotensin II receptor antagonist and a diuretic, hydrochlorothiazide and is used to treat high blood pressure.

For more information Call us ✆ +91 9111-179961 or Visit Dollar Advisory